10-Q: SelectQuote Q2 FY26: Revenue Up, Debt Refinanced, Legal Battles Persist

SelectQuote reports a 12% revenue increase for the six months ended December 31, 2025, driven by its Healthcare Services segment, alongside a significant debt refinancing and ongoing legal challenges.

Summary

• Total revenue increased 12% to $865.9 million for the six months ended December 31, 2025, compared to $773.3 million in the prior year.
• Net income for the six months ended December 31, 2025, was $38.8 million, up from $8.7 million in the prior year.
• Healthcare Services revenue surged 33% to $452.0 million for the six months, primarily from SelectRx pharmacy, which saw a 17% increase in members.
• Senior segment revenue decreased 8% to $320.5 million for the six months, mainly due to a 5% decrease in approved policies and a 3% decrease in Lifetime Value (LTV) per Medicare Advantage (MA) approved policy.
• Life segment revenue increased 14% to $90.3 million for the six months, driven by a 22% increase in final expense revenue.
• Adjusted EBITDA for the six months decreased 39% to $52.7 million from $85.8 million, primarily due to lower Senior segment performance and increased marketing expenses in Life.
• Successfully refinanced all outstanding debt under the Senior Secured Credit Facility with a new $415.0 million credit facility (2026 Credit Agreement) on January 8, 2026, extending maturities to January 8, 2031.
• Ongoing legal proceedings include multiple securities class actions, a stockholder derivative suit, and a Federal False Claims Act qui tam action by the U.S. Attorney's Office.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed but cautiously optimistic report. While strong revenue growth in Healthcare Services and significant debt refinancing are positive, the decline in the core Senior segment's performance and Adjusted EBITDA, coupled with ongoing legal challenges, temper overall enthusiasm.

Positives

• Total revenue increased 12% for both the three and six months ended December 31, 2025, reaching $537.1 million and $865.9 million, respectively.
• Net income significantly improved to $69.3 million for the three months and $38.8 million for the six months ended December 31, 2025, compared to $53.2 million and $8.7 million in the prior year periods.
• Healthcare Services revenue grew substantially by 26% (three months) and 33% (six months), driven by a 17% increase in SelectRx members.
• Life segment revenue increased 9% (three months) and 14% (six months), with final expense commissions up 25% and 22% respectively, due to increased policies sold.
• Interest expense, net, decreased significantly by 51% (three months) and 50% (six months) due to lower cost of capital from securitization and preferred stock issuance.
• Successful refinancing of all outstanding debt under the Senior Secured Credit Facility with a new $415.0 million credit facility (2026 Credit Agreement) on January 8, 2026, extending maturities to January 8, 2031.
• Change in fair value of warrants resulted in a gain of $19.3 million (three months) and $34.3 million (six months), positively impacting income.

Negatives

• Senior segment revenue decreased 1% for the three months and 8% for the six months ended December 31, 2025, primarily due to a 5% decrease in approved policies for the six-month period.
• Adjusted EBITDA decreased by 3% for the three months and 39% for the six months ended December 31, 2025, to $84.7 million and $52.7 million, respectively.
• Healthcare Services Adjusted EBITDA decreased by 62% for the three months ended December 31, 2025, to $0.8 million, despite revenue growth, due to a significant increase in cost of goods sold (pharmacy revenue) and compensation costs.
• Life segment Adjusted EBITDA decreased by 24% for the three months and 16% for the six months ended December 31, 2025, due to increased marketing expenses and cost of commissions.
• Marketing and advertising expenses increased 7% (three months) and 3% (six months), driven by higher lead costs and increased utilization of flex hiring leading to a shift in agent mix (fewer tenured core agents).
• An impairment charge of $1.0 million was recognized for a full write-off of an equity-method investment during the six months ended December 31, 2025.
• The company is in a three-year cumulative loss position, leading to a valuation allowance of $29.6 million for deferred tax assets.
• An expected loss on extinguishment of approximately $8.7 million is anticipated in Q3 FY2026 due to debt refinancing.

Risks

• Multiple securities class action lawsuits (Hartel, WPBPPF, Pahlkotter) and stockholder derivative suits (Jadlow, Roszel) are ongoing, alleging securities fraud, misstatements, omissions, breach of fiduciary duty, and waste of corporate assets.
• A qui tam action (DOJ Action) filed by the U.S. Attorney's Office alleges violations of the Federal False Claims Act due to improper sales and marketing practices, which the company plans to defend vigorously.
• Exposure to interest rate risk on variable-rate debt; a hypothetical 100 basis point increase in market interest rates would increase annualized interest expense by approximately $3.4 million.
• Significant customer concentration, with three insurance carrier customers (UHC, Humana, Aetna) accounting for 40%, 14%, and 12% of total revenue, respectively, for the six months ended December 31, 2025.
• Seasonality of the Senior segment, with highest revenue in the second and third quarters due to Medicare annual and open enrollment periods, leading to fluctuations in cash flows and working capital requirements.
• Reliance on management estimates for revenue recognition, commissions receivable, income taxes, share-based compensation, and valuation of intangible assets, goodwill, and liability classified warrants, where actual amounts could differ significantly.
• Working capital requirements to fund upfront marketing and advertising costs for new policies, as commission payments are received over time.
• Increased utilization of flex hiring has led to a shift in agent mix, with fewer tenured core agents, potentially impacting overall close rates and productivity.

Future Outlook

Management believes existing cash, cash equivalents, funds available under the revolving credit facility, and cash provided from operations will be sufficient to fund normal working capital, investments, and debt services for at least the next 12 months. The company expects to recognize a loss on extinguishment of approximately $8.7 million in the third quarter of fiscal year 2026 due to the debt refinancing. The 2026 Revolving Credit Facility includes a seasonal flex feature, increasing commitments to $90.0 million in January and December each year to support peak operational cycles. The company will continue to evaluate the realizability of its deferred tax assets, and the impact of new U.S. tax legislation (OBBB) on the estimated 2026 annual effective tax rate is not expected to be material.

Management Comments

• "Our strategy is focused on delivering more comprehensive and personalized healthcare solutions that meet the evolving needs of our senior customers."
• "We have built our business model to maximize commissions collected over the life of an approved policy, a metric we refer to as lifetime value of commissions or LTV, which is a key component to our overall profitability."
• "SelectQuote has a long history of successful DTC product distribution and consumer engagement, and we bring this same capability to healthcare services."
• "We continue to look for more opportunities to leverage our strengths to expand our healthcare services business."
• "Management expects that our existing cash, cash equivalents, funds available under the revolving credit facility and cash provided from operations will be sufficient to finance normal working capital needs, investments in properties, facilities and equipment and debt services."
• "The Company currently believes that none of the above matters [legal proceedings] will have a material adverse effect on its operations, financial condition or liquidity; however, depending on how the matters progress, they could be costly to defend and could divert the attention of management and other resources from operations."

Industry Context

StockSavvy.ai notes that SelectQuote's strategic shift towards healthcare services, particularly SelectRx and chronic care management, aligns with a broader industry trend of insurance distributors diversifying into value-added health services to enhance customer engagement and lifetime value. The decline in the Senior segment's approved policies, coupled with increased marketing costs and a shift to less tenured agents, suggests competitive pressures in the core Medicare Advantage market, where customer acquisition costs are rising. The growth in pharmacy revenue indicates successful execution in this diversification strategy, potentially offsetting some of the challenges in traditional insurance distribution.

Comparison to Industry Standards

• The filing does not provide specific comparable companies or industry benchmarks for direct comparison.
• The LTV per MA approved policy decreased by 4% for the three months and 3% for the six months, primarily due to shifts in carrier mix, plan terminations, and changes to plan designs. This suggests potential challenges in maintaining LTVs in a dynamic Medicare Advantage market, which could be a broader industry trend or specific to SelectQuote's carrier relationships.
• The 17% increase in SelectRx members and 21% increase in prescriptions per day for the three months ended December 31, 2025, indicates strong growth in the healthcare services segment, which could be outperforming some traditional pharmacy benefit managers or direct-to-consumer health service providers, though specific comparative data is not provided.

Corporate Governance

Legal Proceedings

• **Securities Class Actions (Consolidated as *In re SelectQuote, Inc. Securities Litigation*):** Filed in U.S. District Court for the Southern District of New York, alleging violations of Sections 10(b), 20(a), and Rule 10b-5 of the Exchange Act, and Sections 11, 12(a)(2), and 15 of the Securities Act. The court dismissed the second amended complaint on April 3, 2025, and plaintiffs filed an appeal on May 5, 2025, with oral argument scheduled for February 27, 2026.
• **Stockholder Derivative Suit (*Jadlow v. Danker, et al.*):** Filed in U.S. District Court for the Southern District of New York, alleging violations of Section 14(a) of the Exchange Act, breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets. The action is stayed pending resolution of the motion to dismiss the Securities Class Action.
• **DOJ Action (Qui Tam Action *United States ex rel. Shea v. eHealth, Inc., et al.*):** The U.S. Attorney's Office for the District of Massachusetts filed a complaint partially intervening in this action, alleging violations of the Federal False Claims Act due to improper sales and marketing practices. Motions to dismiss are pending after a hearing on January 21, 2026.
• **Securities Class Action (*Pahlkotter v. SelectQuote, Inc., et al.*):** Filed in U.S. District Court for the Southern District of New York, relating to allegations in the DOJ Action. An amended complaint was filed on January 16, 2026, adding Robert Grant (Company's President) as an individual defendant.
• **Stockholder Derivative Action (*Roszel v. Hawks, et al.*):** Filed in U.S. District Court for the Southern District of New York, alleging violations of Section 14(a) of the Exchange Act, breach of fiduciary duty, unjust enrichment, and waste of corporate assets related to the DOJ Action events. The action was accepted as related to the Pahlkotter Action on February 2, 2026.

Related Party Transactions

• SelectRx leases the Monaca facility from an Executive Vice President of SelectRx. The Company expects to incur $3.6 million in total rental payments over the initial ten-year term plus an additional five-year extension option that it is reasonably certain to exercise.
• No other material related-party transactions were reported during the three and six months ended December 31, 2025, and there were no outstanding balances due to or from related parties as of December 31, 2025.

Stakeholder Impact

• **Shareholders**: Face potential dilution from warrants, significant uncertainty from ongoing legal proceedings, but benefit from improved liquidity and extended debt maturities due to refinancing. Mixed financial performance presents a complex investment picture.
• **Employees**: The Life segment saw increased agent headcount, particularly through flex hiring, impacting compensation costs. Share-based compensation plans remain a component of employee incentives.
• **Customers**: Continued growth in SelectRx members indicates successful engagement in healthcare services. However, allegations of improper sales practices in the DOJ Action could potentially impact customer trust and regulatory scrutiny.
• **Creditors**: The debt refinancing improves the company's capital structure and extends maturities, reducing immediate repayment pressure. The company maintains compliance with debt covenants, providing stability.
• **Insurance Carrier Partners**: Shifts in carrier mix and changes to plan designs are impacting the LTV per MA approved policy, suggesting dynamic relationships and potential adjustments in commission structures.

Next Steps

• Oral argument before the Second Circuit for the Securities Class Action appeal is scheduled for February 27, 2026.
• Quarterly principal repayments for the new 2026 Term Loan commence on April 1, 2026.
• The company will continue to evaluate the realizability of its deferred tax assets.
• Management will continue to look for opportunities to leverage strengths to expand the healthcare services business.

Key Dates

Recommendation

The company demonstrates strong growth in its Healthcare Services segment and has successfully refinanced its debt, improving its capital structure and liquidity. However, the decline in the core Senior segment's profitability, coupled with increased marketing expenses and a significant number of ongoing legal challenges, introduces considerable uncertainty. A 'Hold' recommendation is appropriate as investors await clearer operational improvements in the Senior segment and resolution of the legal proceedings, which could significantly impact future financial performance and shareholder value.

Keywords

SelectQuote, SLQT, Insurance, Healthcare Services, Medicare Advantage, SelectRx, Financial Results, Q2 2026, 10-Q, SEC Filing, Debt Refinancing, Legal Proceedings, Commissions, Pharmacy Revenue, Adjusted EBITDA, Warrants, Corporate Governance, Risk Factors